Thursday, 15 June 2017

New Research Explores on Myelodysplastic Syndrome - Pipeline Review, H1 2017

Myelodysplastic Syndrome - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 12, 66, 56, 2, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 8, 7, 2, 1 and 2 molecules, respectively.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG AbbVie Inc Acceleron Pharma Inc Actinium Pharmaceuticals Inc Aeglea BioTherapeutics Inc Agios Pharmaceuticals Inc Aileron Therapeutics Inc Altor BioScience Corp Amgen Inc Apogenix GmbH Aprea AB arGEN-X BV Ariad Pharmaceuticals Inc Arno Therapeutics Inc Array BioPharma Inc Astex Pharmaceuticals Inc Atara Biotherapeutics Inc Bayer AG Bellicum Pharmaceuticals Inc BerGenBio ASA Bio-Path Holdings Inc BioLineRx Ltd BioLite Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc Cantex Pharmaceuticals Inc Celgene Corp Celldex Therapeutics Inc Cellectis SA Cellerant Therapeutics Inc Celyad SA Cornerstone Pharmaceuticals Inc CrystalGenomics Inc CTI BioPharma Corp Cyclacel Pharmaceuticals Inc Daiichi Sankyo Company Ltd Deciphera Pharmaceuticals LLC Eisai Co Ltd Eleos Inc Eli Lilly and Company EpiZyme Inc F. Hoffmann-La Roche Ltd Fate Therapeutics Inc Forma Therapeutics Inc Fortress Biotech Inc Fujifilm Corp Gamida Cell Ltd GlaxoSmithKline Plc H3 Biomedicine Inc IGF Oncology LLC Immune System Key Ltd ImmunoGen Inc Incyte Corp Io Therapeutics Inc Jazz Pharmaceuticals Plc Jiangsu Hansoh Pharmaceutical Group Co Ltd Johnson & Johnson JW Pharmaceutical Corp Kainos Medicine Inc KaloBios Pharmaceuticals Inc Karyopharm Therapeutics Inc Kiadis Pharma NV Kyowa Hakko Kirin Co Ltd Les Laboratoires Servier SAS Lixte Biotechnology Holdings Inc MacroGenics Inc Mateon Therapeutics Inc medac GmbH MediGene AG MedImmune LLC Medivir AB MEI Pharma Inc Merck & Co Inc Merus NV Mesoblast Ltd Millennium Pharmaceuticals Inc Mirati Therapeutics Inc Novartis AG OncoImmune Inc Onconova Therapeutics Inc OncoTherapy Science Inc Opsona Therapeutics Ltd Pfizer Inc Pharma Mar SA Plexxikon Inc Regen BioPharma Inc Rich Pharmaceuticals Inc Seattle Genetics Inc Sorrento Therapeutics Inc Stemline Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Sunesis Pharmaceuticals Inc Syndax Pharmaceuticals Inc Takara Bio Inc Targazyme Inc Teva Pharmaceutical Industries Ltd Tolero Pharmaceuticals Inc Tragara Pharmaceuticals Inc Trillium Therapeutics Inc VasGene Therapeutics Inc
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home